Erik Harris

Insider Reports History

Location
Redwood City, CA
Signature
/s/ Erik Harris
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Erik Harris:

Company Role Class Num Shares Value Price $ Report Date Ownership
Ultragenyx Pharmaceutical Inc. EVP & Chief Commercial Officer Common Stock 87,855 $3,698,696 $42.10 03 Mar 2025 Direct
Denali Therapeutics Inc. Director Common Stock 17,052 $347,690 $20.39 31 May 2024 Direct
Rezolute, Inc. Director Common Shares 21,000 $192,990 $9.19 19 Nov 2025 Direct
Inozyme Pharma, Inc. Director Stock Option (right to buy) 56,000 03 Oct 2024 Direct
Ultragenyx Pharmaceutical Inc. EVP & Chief Commercial Officer Stock Option (Right to Buy) 30,246 01 Mar 2025 Direct
Denali Therapeutics Inc. Director Stock Option (right to buy) 17,901 31 May 2024 Direct
Rezolute, Inc. Director Director Stock Option (Right to Buy) 12,000 19 Nov 2025 Direct

Insider Reports Filed by Erik Harris

Symbol Company Period Transactions Value $ Form Type Role Filing Time
RZLT Rezolute, Inc. 19 Nov 2025 2 $0 4 Director 21 Nov 2025, 17:02
RZLT Rezolute, Inc. 25 Mar 2025 1 $0 4 Director 26 Mar 2025, 19:37
RZLT Rezolute, Inc. 25 Mar 2025 0 $0 3 Director 26 Mar 2025, 19:31
RARE Ultragenyx Pharmaceutical Inc. 01 Mar 2025 4 -$635,836 4 EVP & Chief Commercial Officer 04 Mar 2025, 20:06
INZY Inozyme Pharma, Inc. 03 Oct 2024 1 $0 4 Director 07 Oct 2024, 16:37
INZY Inozyme Pharma, Inc. 03 Oct 2024 0 $0 3 Director 07 Oct 2024, 16:35
DNLI Denali Therapeutics Inc. 31 May 2024 2 $0 4 Director 04 Jun 2024, 18:27
RARE Ultragenyx Pharmaceutical Inc. 01 Mar 2024 4 -$256,328 4 EVP & Chief Commercial Officer 05 Mar 2024, 20:08
RARE Ultragenyx Pharmaceutical Inc. 05 Sep 2023 1 -$227,760 4 EVP & Chief Commercial Officer 06 Sep 2023, 17:51
RARE Ultragenyx Pharmaceutical Inc. 19 Jun 2023 1 -$14,701 4 EVP & Chief Commercial Officer 21 Jun 2023, 18:17
DNLI Denali Therapeutics Inc. 01 Jun 2023 2 $0 4 Director 05 Jun 2023, 18:02
RARE Ultragenyx Pharmaceutical Inc. 01 Mar 2023 4 -$165,796 4 EVP & Chief Commercial Officer 03 Mar 2023, 18:51
RARE Ultragenyx Pharmaceutical Inc. 19 Jun 2022 1 -$16,160 4 EVP & Chief Commercial Officer 22 Jun 2022, 19:27
RARE Ultragenyx Pharmaceutical Inc. 01 Mar 2022 3 -$180,740 4 EVP & Chief Commercial Officer 03 Mar 2022, 17:11
DNLI Denali Therapeutics Inc. 07 Feb 2022 0 $0 3/A Director 14 Feb 2022, 19:32
DNLI Denali Therapeutics Inc. 03 Feb 2022 2 $0 4 Director 07 Feb 2022, 17:54
DNLI Denali Therapeutics Inc. 03 Feb 2022 0 $0 3 Director 07 Feb 2022, 17:51
RARE Ultragenyx Pharmaceutical Inc. 14 Oct 2021 1 -$24,585 4 EVP & Chief Commercial Officer 18 Oct 2021, 18:58
RARE Ultragenyx Pharmaceutical Inc. 06 Jul 2021 1 -$34,324 4 EVP & Chief Commercial Officer 08 Jul 2021, 11:56
RARE Ultragenyx Pharmaceutical Inc. 19 Jun 2021 2 -$95,670 4 EVP & Chief Commercial Officer 23 Jun 2021, 17:55
RARE Ultragenyx Pharmaceutical Inc. 06 May 2021 2 -$79,572 4 EVP & Chief Commercial Officer 10 May 2021, 18:10